Jazz Pharmaceuticals JAZZ Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue from Contract with Customer, Excluding Assessed Tax by Product | ||||||
| Defitelio/defibrotide | $206.13M-1.7% | $199.43M-7.9% | $198.21M-5.6% | $212.27M+10.6% | $209.59M+8.8% | |
| Epidiolex/Epidyolex | $1.09B+10.1% | $1.06B+8.9% | $1.05B+11.6% | $996.04M+10.7% | $991.41M+15.9% | |
| High-sodium oxybate AG royalty revenue | $199.08M-8.1% | $211.68M-2.7% | $211.29M+4.8% | $216.5M+25.6% | $216.53M+74.9% | |
| Modeyso | $89.44M— | $48.04M— | $11.5M— | $470K— | —— | |
| Other | $12.56M-31.0% | $20.16M+75.7% | $19.83M+57.5% | $19.91M+50.1% | $18.2M+30.2% | |
| Rylaze/Enrylaze | $412.39M+2.5% | $402.89M-1.9% | $396.21M-3.6% | $395.13M-5.3% | $402.3M-2.1% | |
| Vyxeos | $143.77M-10.2% | $146.67M-9.8% | $165.18M+5.7% | $161.91M+6.7% | $160.07M+12.1% | |
| Xyrem | $139.99M-32.3% | $145.99M-37.6% | $157.5M-45.9% | $179.95M-49.8% | $206.78M-54.6% | |
| Xywav | $1.72B+14.5% | $1.66B+12.5% | $1.59B+13.0% | $1.55B+14.6% | $1.5B+14.7% | |
| Zepzelca | $345.28M+12.0% | $307.28M-4.1% | $295.16M-6.6% | $301.71M-2.1% | $308.22M+3.6% | |
| Ziihera | $36.14M+1,084% | $24.84M+2,263% | $17.35M— | $9.04M— | $3.05M— | |
| Revenue from Contract with Customer, Excluding Assessed Tax by Geography | ||||||
| All other | $95.28M+5.8% | $94.88M-1.3% | $94.86M+5.7% | $99.61M+18.0% | $90.02M+11.7% | |
| Europe | $350.48M+7.9% | $341.68M+9.3% | $334.65M+9.4% | $325.57M+9.4% | $324.96M+18.3% | |
| U.S. | $3.99B+9.4% | $3.83B+4.7% | $3.73B+3.6% | $3.66B+3.8% | $3.65B+4.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Jazz Pharmaceuticals break its business down?
- Jazz Pharmaceuticals (JAZZ) reports revenue from contract with customer, excluding assessed tax by product across 12 parts — Defitelio/defibrotide, Epidiolex/Epidyolex, High-sodium oxybate AG royalty revenue, Modeyso and Other. Each is extracted from the segment footnotes and tracked over time.
- Where does Jazz Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Jazz Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
